Technical Analysis for PRPO - Precipio, Inc.

Grade Last Price % Change Price Change
D 6.10 0.00% 0.00
PRPO closed unchanged on Monday, March 18, 2024, on 34 percent of normal volume. It ran into resistance at its 50 day moving average. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
Earnings due: Apr 1
*** please verify all earnings dates ***
0 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Down Down

Date Alert Name Type % Chg
20 DMA Resistance Bearish 0.00%
50 DMA Resistance Bearish 0.00%
BB Squeeze Ended Range Expansion 0.00%
Gapped Up Strength 0.00%
Oversold Stochastic Weakness 0.00%
20 DMA Resistance Bearish 0.00%
50 DMA Resistance Bearish 0.00%
Bollinger Band Squeeze Range Contraction 0.00%
Stochastic Reached Oversold Weakness 0.00%
Gapped Up Strength 0.00%

   Recent Intraday Alerts

Alert Time
20 DMA Support about 14 hours ago
10 DMA Support about 14 hours ago
50 DMA Support about 14 hours ago
Rose Above 20 DMA about 15 hours ago
Up 5% about 15 hours ago

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Precipio, Inc. Description

Precipio, Inc., formerly Transgenomic, Inc., is a biotechnology company. The Company is engaged in advancing personalized medicine for the detection and treatment of cancer, and inherited diseases through its molecular technologies and clinical and research services. The Company operates through its Laboratory Services segment. The Company is engaged in the provision of its Multiplexed ICE COLD-PCR (MX-ICP) product to the clinical market, enabling the use of blood and other bodily fluids for diagnosis, monitoring and treatment of cancer. MX-ICP amplifies the ability to detect genetic mutations by approximately 100 to 400 fold. MX-ICP is validated internally on sequencing platforms, including Sanger, Next Gen Sequencing and Digital polymerase chain reaction (PCR). Its laboratory in Omaha, Nebraska is focused on providing genetic analytical services related to oncology and pharmacogenomics research services supporting Phase II and Phase III clinical trials conducted.


Classification

Sector: Healthcare
Industry: Diagnostics & Research
Keywords: Biotechnology Cancer Biology Disease Natural Sciences Treatment Of Cancer Molecular Biology Genomics Molecular Diagnostics Laboratory Services Analytical Services Laboratory Techniques Personalized Medicine Polymerase Chain Reaction Pharmacogenomics Molecular Technologies

Is PRPO a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 8.99
52 Week Low 0.2505
Average Volume 7,168
200-Day Moving Average 4.20
50-Day Moving Average 6.31
20-Day Moving Average 6.33
10-Day Moving Average 6.21
Average True Range 0.34
RSI (14) 44.13
ADX 12.63
+DI 18.23
-DI 23.33
Chandelier Exit (Long, 3 ATRs) 5.72
Chandelier Exit (Short, 3 ATRs) 7.03
Upper Bollinger Bands 6.71
Lower Bollinger Band 5.94
Percent B (%b) 0.2
BandWidth 12.15
MACD Line -0.08
MACD Signal Line -0.04
MACD Histogram -0.0407
Fundamentals Value
Market Cap 8.66 Million
Num Shares 1.42 Million
EPS -7.47
Price-to-Earnings (P/E) Ratio -0.82
Price-to-Sales 0.67
Price-to-Book 0.70
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 6.66
Resistance 3 (R3) 6.72 6.59 6.56
Resistance 2 (R2) 6.59 6.45 6.56 6.53
Resistance 1 (R1) 6.35 6.36 6.29 6.29 6.50
Pivot Point 6.22 6.22 6.19 6.19 6.22
Support 1 (S1) 5.98 6.08 5.92 5.92 5.70
Support 2 (S2) 5.85 5.99 5.82 5.67
Support 3 (S3) 5.61 5.85 5.64
Support 4 (S4) 5.55